Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.85Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Health Score : 4.85Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
106.39
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
234.05
P/B RATIO
3.73
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
5.52
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
68.47
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹947.9 as on Sep 1, 2026.
Growth Score : 4.00The company shows good operating profit and asset growth. However, revenue and net income growth are not doing good. The weighted average calculation shows that while some areas are growing, others are lagging. The company needs to focus on driving revenue and net income growth to achieve more balanced and sustainable growth.
Revenue Growth RatePoor
Operating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 24.44 | 18.93 | 22.97 | 12.58 | -12.04 |
| Operating Profit Growth Rate | 89.66 | 52.73 | 32.14 | 6.31 | -65.25 |
| Earnings Per Share (EPS) Growth | 98.32 | 2464.58 | 60.09 | 8.15 | -79.39 |
| Asset Growth Rate | -10.19 | 10.26 | 26.86 | 8.62 | 13.21 |
| Net Income Growth Rate | 98.29 | 2400 | 100 | 8.7 | -79 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 7 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 21 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Orchid Pharma Ltd. is an Indian pharmaceutical company primarily engaged in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). It specializes in beta-lactam antibiotics, particularly cephalosporins, serving both domestic and international markets with a focus on high-quality, specialty products.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Orchid Pharma Ltd's P/E ratio (TTM) is 106.39, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Orchid Pharma Ltd's P/B ratio is 3.73, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Orchid Pharma Ltd's P/S ratio is 5.52, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Orchid Pharma Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Orchid Pharma Ltd's EV/EBITDA ratio is 68.47.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Orchid Pharma Ltd's ROE is 1.63%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Orchid Pharma Ltd's ROA is 2.15%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Orchid Pharma Ltd's ROCE is 3%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Orchid Pharma Ltd's operating margin is 5.06%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Orchid Pharma Ltd's net margin is 2.59%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Orchid Pharma Ltd's current ratio is 2.84.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Orchid Pharma Ltd's debt-to-equity ratio is 0.27.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Orchid Pharma Ltd's interest coverage ratio is 2.62.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Orchid Pharma Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Orchid Pharma Ltd's EPS is -79.39.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹947.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1992 (as Orchid Chemicals & Pharmaceuticals Ltd.)
Headquarters: Chennai, Tamil Nadu
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Cephalosporin Antibiotics, Contract Manufacturing
Stock Listing: NSE (ORCHPHARMA), BSE (524372)
Promoter: Dhanuka Group / Samir Kumar Dhanuka
Founded in 1992 as Orchid Chemicals & Pharmaceuticals Ltd., the company grew to be a prominent player in cephalosporin APIs. Facing financial distress, it underwent a Corporate Insolvency Resolution Process. In 2020, Dhanuka Laboratories Limited (part of the Dhanuka Group) acquired the company, leading to its successful relisting on stock exchanges in 2021 as Orchid Pharma Ltd., now focused on rejuvenation and expansion.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | N/A | Operating Profit |
| Finished Dosage Forms (FDFs) | N/A | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Focuses on the development and manufacturing of a wide range of APIs, particularly strong in beta-lactam antibiotics (cephalosporins). Caters to global markets.
Finished Dosage Forms (FDFs): Manufactures various pharmaceutical formulations, including oral solids, injectables, and liquid orals. Products are marketed in India and internationally.
Mr. Samir Kumar Dhanuka - Managing Director. He played a pivotal role in the acquisition and successful turnaround of Orchid Pharma, leveraging extensive experience from the Dhanuka Group in pharmaceutical manufacturing and operations.
Underwent Corporate Insolvency Resolution Process (CIRP) and was successfully acquired by Dhanuka Group in 2020. The company was subsequently relisted on Indian stock exchanges in 2021, marking a significant turnaround.
The Orchid Pharma Ltd share price today is ₹947.90 on NSE (ORCHPHARMA), as of 26 Sept 2026.
As of 25 Sept 2026, Orchid Pharma Ltd share price is ₹947.90, with previous close ₹947.90. Today's range is ₹947.90 to ₹947.90. The 52-week range is ₹480 to ₹1143.50.
As of today, Orchid Pharma Ltd's market cap is ₹4,474.09 crore (Small Cap).
Orchid Pharma Ltd's current P/E ratio is 106.39, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.70.
Orchid Pharma Ltd's current P/B ratio is 3.73.
Orchid Pharma Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Orchid Pharma Ltd's EPS (TTM) is ₹-79.39.
Orchid Pharma Ltd. is an Indian pharmaceutical company primarily engaged in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). It specializes in beta-lactam antibiotics, particularly cephalosporins, serving both domestic and international markets with a focus on high-quality, specialty products.
Orchid Pharma Ltd is promoted by Dhanuka Group / Samir Kumar Dhanuka, holding 69.84% as of 25 Sept 2026.
Orchid Pharma Ltd is listed on NSE (ORCHPHARMA) and BSE (524372). Its next quarterly results are expected on August 2024 (Q1 FY25).
Financial Health & Prudence
